Publications by authors named "Jean-Charles Vermion"

Purpose: Identifying pre/perioperative factors that predict corneal endothelial-cell loss (ECL) after phacoemulsification may reveal ways to reduce ECL. Our literature analysis showed that 37 studies have investigated one or several such factors but all have significant limitations. Therefore, the data of a large randomized controlled trial (PERCEPOLIS) were subjected to post-hoc multivariate analysis determining the ability of nine pre/perioperative variables to predict ECL.

View Article and Find Full Text PDF

Purpose: The long-term clinical outcomes, postoperative complications, and graft survival of Descemet-membrane endothelial keratoplasty (DMEK) remain poorly understood. We retrospectively assessed these variables in all consecutive eyes that underwent DMEK for any indication in 2014-2018. The findings were compared to the long-term DMEK studies of five other groups (3-10-year follow-up).

View Article and Find Full Text PDF

Descemet membrane endothelial keratoplasty (DMEK) restores visual acuity in patients with progressive corneal endothelial diseases such as Fuchs endothelial corneal dystrophy (FECD). However, patients often prefer to delay the surgery as long as possible, even though outcomes are poorer in advanced FECD. A recent study proposed that preoperative central corneal thickness (CCT) of ≥625 μm associated with worse best spectacle-corrected visual acuity (BSCVA) after DMEK for FECD.

View Article and Find Full Text PDF

Systemic administration of agents that inhibit vascular endothelial growth factor (VEGF) and therefore vascular proliferation is often used to treat various cancers. However, these agents are associated with a number of side effects, including proteinuria and renal injury. Intravitreal injection of anti-VEGF agents has become the cornerstone of macular disease treatment.

View Article and Find Full Text PDF
Article Synopsis
  • This study looked at the changes in corneal transplantation practices over a 21-year period (2000-2020) in a French ophthalmology department, noting significant increases in annual transplant numbers.
  • Initially, penetrating keratoplasty (PKP) was the only method used, but newer techniques like Descemet stripping automated endothelial keratoplasty (DSAEK) and Descemet membrane endothelial keratoplasty (DMEK) were introduced, leading to a surge in their usage.
  • The research also highlighted a shift in the most common conditions treated with corneal transplants, with an increased focus on pseudophakic bullous keratopathy (PBK) and Fuchs endothelial cell dystrophy (FECD
View Article and Find Full Text PDF

Low postoperative endothelial-cell density (ECD) plays a key role in graft failure after Descemet-membrane endothelial keratoplasty (DMEK). Identifying pre/perioperative factors that predict postoperative ECD could help improve DMEK outcomes. This retrospective study was conducted with consecutive adult patients with Fuchs-endothelial corneal dystrophy who underwent DMEK in 2015-2019 and were followed for 12 months.

View Article and Find Full Text PDF
Article Synopsis
  • A study investigated the safety and effectiveness of transepithelial photorefractive keratectomy (TransPRK) for high myopia, specifically using the ASLA-SCHWIND laser system without the typical use of mitomycin-C to prevent corneal haze.
  • Results from 69 eyes showed a significant improvement in uncorrected and best spectacle-corrected visual acuity after surgery, with high efficacy (95.7%) and safety rates (95.7%), and minimal haze complications (none at grades 3-4).
  • The findings suggest that performing TransPRK without mitomycin-C may be a viable option for treating high myopia, demonstrating good visual outcomes and predictability.
View Article and Find Full Text PDF

Purpose: It remains unclear whether preoperative central graft thickness (CGT) contributes to visual outcomes of Descemet stripping automated endothelial keratoplasty (DSAEK). This retrospective cohort study examined the ability of preoperative and postoperative CGT to predict 12-month best spectacle-corrected visual acuity (BSCVA) after DSAEK for Fuchs endothelial corneal dystrophy/moderate pseudophakic bullous keratopathy/second graft.

Methods: All consecutive patients who underwent DSAEK in 2015 to 2018 were included.

View Article and Find Full Text PDF